Donepezil Nanofiber Transdermal Patch for Alzheimer's
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current oral donepezil formulations for Alzheimer's disease treatment are associated with significant side effects and inadequate dosage control, and existing transdermal forms fail to provide consistent drug release.
Innovation Solution
Development of donepezil-containing nanofibers using the electrospinning method, which creates a transdermal drug delivery system in patch or plaster form with a controlled release mechanism, utilizing biocompatible polymers and surfactants to ensure optimal homogeneity and controlled drug release.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of operation
If oral donepezil formulations are used, then the drug can be administered conveniently, but significant side effects occur including nausea, diarrhea, insomnia, vomiting, and gastrointestinal ailments
Solution Approach 1:
The patent introduces a transdermal delivery system as an intermediary between the drug and the body's internal systems. The donepezil is delivered through the skin rather than being ingested, using a patch or plaster that releases the drug through the skin barrier into the bloodstream, thereby avoiding direct contact with the gastrointestinal tract and reducing GI side effects
Solution Approach 2:
The patent replaces the mechanical/oral ingestion route with a transdermal delivery mechanism. Instead of swallowing tablets or capsules that travel through the digestive system, the drug is delivered through electrospun nanofibers that release donepezil through the skin, substituting the oral-mechanical pathway with a transdermal-physiological pathway
2Object-generated harmful factors
If delayed release oral formulations are used, then side effects are alleviated to some extent, but they are not eliminated entirely and patient compliance remains insufficient
Solution Approach 1:
The patent changes the delivery parameter from oral delayed-release to transdermal controlled-release. The electrospun nanofiber matrix provides sustained release of donepezil through the skin, maintaining steady drug levels in the bloodstream over extended periods (up to 7 days), which eliminates the need for frequent dosing and significantly improves patient compliance while fully eliminating GI side effects
3Object-generated harmful factors
If conventional transdermal applications are used, then side effects are reduced, but the drug dosage cannot be controlled properly and necessary dosage cannot be provided in desired periods
Solution Approach 1:
The patent utilizes electrospun nanofibers with controlled porosity to achieve precise dosage control. The porous structure of the nanofiber mat allows for controlled diffusion of donepezil at predetermined rates, enabling accurate dosing over extended periods while maintaining the benefits of transdermal delivery and avoiding the dosage control problems of conventional transdermal patches
4Object-generated harmful factors
If oral formulations are used, then high gastric acid secretion occurs due to cholinergic activity, but changing to transdermal forms previously failed to provide consistent release
Solution Approach 1:
The patent employs composite electrospun nanofiber materials comprising biocompatible polymers (such as poly(lactic-co-glycolic acid) or polyethylene glycol) blended with donepezil. This composite structure provides both the controlled release properties needed for consistent drug delivery and the transdermal delivery mechanism needed to eliminate gastric acid secretion issues, achieving both goals simultaneously
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The nanofiber-based transdermal system provides a consistent and prolonged release of donepezil, reducing side effects and improving patient compliance, with enhanced bioavailability and stability of the active ingredient.
Implementation Method 1
electrospinning method is specifically preferred for obtaining nanofibers. This method is advantageous in obtaining broadened surface area and increased porousness transdermal dosage forms
Data Source
Figure 1
Figure 2~3
Figure 4
AI summary
The present invention relates to the use of nanofibers comprising donepezil or a pharmaceutically acceptable salt thereof as active ingredient and at least one polymer as a transdermal dosage form for treatment of Alzheimer type dementia.